» Articles » PMID: 33528791

UBE2R2-AS1 Inhibits Xenograft Growth in Nude Mice and Correlates with a Positive Prognosis in Glioma

Overview
Journal J Mol Neurosci
Date 2021 Feb 2
PMID 33528791
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous study showed that the lncRNA UBE2R2-AS1 inhibits the growth and invasion of glioma cells and promotes apoptosis through the miR-877-3p/TLR4 pathway. In this study, it was further found that the expression of UBE2R2-AS1 in glioma tissues was decreased significantly, and gradually decreased with increasing clinical stage. Chi-square analysis showed that the expression of UBE2R2-AS1 was significantly correlated with the WHO stage of tumor and epilepsy. Using Kaplan-Meier univariate survival analysis, it was found that the expression of UBE2R2-AS1 correlated positively with the overall survival of patients with glioma, while multiple Cox regression analysis showed that the expression of UBE2R2-AS1 correlated positively with the overall survival of patients with glioma as a protective factor for glioma prognosis. The analysis of data from TCGA also showed that patients with high UBE2R2-AS1 levels or low miR-877-3p expression were more likely to have good survival outcomes. Further construction of a glioma xenograft model in nude mice showed that UBE2R2-AS1 overexpression inhibited the growth of tumors, and the inhibition of miR-877-3p expression had a similar effect. Simultaneous UBE2R2-AS1 overexpression and miR-877-3p inhibition further decreased the growth rate of tumors in nude mice. Taken together, the results of our study suggest that UBE2R2-AS1 is an important tumor suppressor gene in glioma, which may be a good marker and treatment target for the clinical detection of glioma.

Citing Articles

Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.

Du Y, Li R, Fu D, Zhang B, Cui A, Shao Y CNS Neurosci Ther. 2024; 30(4):e14717.

PMID: 38641945 PMC: 11031674. DOI: 10.1111/cns.14717.


A Comprehensive Study on Signal Transduction and Therapeutic Role of miR-877 in Human Cancers.

Rafat M, Kohsarian M, Bahiraei M, Nikpoor A Adv Biomed Res. 2023; 12:118.

PMID: 37434921 PMC: 10331537. DOI: 10.4103/abr.abr_412_21.


Metabolism-related long non-coding RNA in the stomach cancer associated with 11 AMMLs predictive nomograms for OS in STAD.

Jin W, Ou K, Li Y, Liu W, Zhao M Front Genet. 2023; 14:1127132.

PMID: 36992704 PMC: 10040790. DOI: 10.3389/fgene.2023.1127132.


LncRNA UBE2R2-AS1, as prognostic marker, promotes cell proliferation and EMT in prostate cancer.

Wang F, Zhao M, Jiang Y, Xia S, Sun D, Zhou D Histol Histopathol. 2022; 38(6):637-645.

PMID: 35916204 DOI: 10.14670/HH-18-505.

References
1.
Ernst C, Morton C . Identification and function of long non-coding RNA. Front Cell Neurosci. 2013; 7:168. PMC: 3788346. DOI: 10.3389/fncel.2013.00168. View

2.
Ghosh D, Nandi S, Bhattacharjee S . Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med. 2018; 7(1):33. PMC: 6191404. DOI: 10.1186/s40169-018-0211-8. View

3.
Kornienko A, Guenzl P, Barlow D, Pauler F . Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013; 11:59. PMC: 3668284. DOI: 10.1186/1741-7007-11-59. View

4.
Li X, Wu Z, Fu X, Han W . Long Noncoding RNAs: Insights from Biological Features and Functions to Diseases. Med Res Rev. 2012; 33(3):517-53. DOI: 10.1002/med.21254. View

5.
Liu Y, Zhao M . lnCaNet: pan-cancer co-expression network for human lncRNA and cancer genes. Bioinformatics. 2016; 32(10):1595-7. DOI: 10.1093/bioinformatics/btw017. View